文献速递消化系统肿瘤

体能状态对dMMR/MSI-H转移性结直肠癌患者免疫检查点抑制策略结局的预后影响

Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2022-06-28

这项在全球三级癌症中心开展的队列研究纳入502例dMMR/MSI-H转移性结直肠癌患者,评估体能状态(PS)对免疫检查点抑制剂疗效的影响。中位随访31.2个月,患者相关PS≥1和肿瘤相关PS≥1均与更差的PFS和OS相关;在肿瘤相关PS≥1亚组中,抗PD-1/抗CTLA-4联合治疗较单药显著改善PFS和OS。

要点

  • 患者相关PS≥1与更差PFS(校正HR 1.73)和OS(校正HR 2.06)相关。
  • 肿瘤相关PS≥1与更差PFS(校正HR 1.61)和OS(校正HR 1.87)相关。
  • 肿瘤相关PS≥1亚组中联合治疗较单药显著改善PFS(HR 0.32)和OS(HR 0.26)。

核心结论

  • 在dMMR/MSI-H转移性结直肠癌患者中,包括PS在内的临床变量全面评估可纳入治疗决策。

研究设计与样本

  • 全球三级癌症中心开展的研究,收集接受抗PD-(L)1单药或抗PD-1/抗CTLA-4联合治疗的dMMR/MSI-H转移性结直肠癌患者数据。
  • 队列共纳入502例患者。

主要发现

  • 中位随访31.2个月,患者相关PS≥1者PFS校正HR 1.73(95%CI 1.06-2.83,p=0.004),OS校正HR 2.06(95%CI 1.13-3.74,p=0.001)。
  • 肿瘤相关PS≥1者PFS校正HR 1.61(95%CI 1.19-2.17,p=0.004),OS校正HR 1.87(95%CI 1.32-2.66,p=0.001)。
  • PS 0亚组中联合治疗较单药PFS HR 0.62(95%CI 0.37-1.02,p=0.059),OS HR 0.59(95%CI 0.32-1.11,p=0.100),未达统计学显著。
  • 患者相关PS≥1亚组中联合治疗较单药PFS HR 0.93(95%CI 0.31-2.83,p=0.899),OS HR 1.22(95%CI 0.34-4.37,p=0.760),无显著差异。
  • 肿瘤相关PS≥1亚组中联合治疗较单药PFS HR 0.32(95%CI 0.19-0.53,p<0.001),OS HR 0.26(95%CI 0.14-0.48,p<0.001),差异显著且有临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors yielded unprecedented outcomes in patients with mismatch repair deficient/ microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC), but clinical decision-making in this rapidly evolving treatment landscape is challenging. Since performance status (PS) represents a well-established prognostic factor in clinical practice, we investigated whether worse PS, overall or related to either patients' frailty or high tumour burden, could affect the outcomes in this whole patients' population and according to immune checkpoint inhibitor treatment type. METHODS: We conducted a global study at Tertiary Cancer Centres and collected data of patients with dMMR/MSI-H mCRC treated with anti- programmed-death (ligand)-1 (PD(L)-1) monotherapy or anti-PD-1/anti- cytotoxic T-lymphocyte antigen 4 combination. RESULTS: The cohort included 502 patients. At a median follow-up of 31.2 months, worse PFS and OS were reported in patients with patient-related PS ≥ 1 (adjusted-HRs: 1.73, 95%CI: 1.06-2.83, p = 0.004 and 2.06, 95%CI: 1.13-3.74, p = 0.001, respectively) and cancer-related PS ≥ 1 (adjusted-HRs: 1.61, 95%CI: 1.19-2.17, p = 0.004 and 1.87, 95%CI: 1.32-2.66, p = 0.001, respectively). Anti-PD-1/anti- cytotoxic T-lymphocyte antigen 4 combination did not provide significantly better survival compared to anti-PD(L)-1 monotherapy in PS 0 subgroup (PFS HR = 0.62, 95%CI: 0.37-1.02, p = 0.059; OS HR = 0.59, 95%CI: 0.32-1.11, p = 0.100) and in patient-related PS ≥ 1 (PFS HR 0.93, 95%CI: 0.31-2.83, p = 0.899; OS HR 1.22, 95%CI: 0.34-4.37, p = 0.760), but the difference was significant and clinically meaningful in the subgroup with cancer-related PS ≥ 1 (PFS HR = 0.32, 95%CI: 0.19-0.53, p < 0.001; OS HR = 0.26, 95%CI: 0.14-0.48, p < 0.001). CONCLUSIONS: In patients with dMMR/MSI-H mCRC, an extensive evaluation of clinical variables including PS may be implemented in the therapy decision-making.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mazzoli G, Cohen R, Lonardi S, et al. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer. 2022. PMID: 35777274. doi:10.1016/j.ejca.2022.05.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。